Seth Klarman Akebia Therapeutics, Inc. Transaction History

Baupost Group LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 13, 2020	SELL	$2.39 - $13.08 $35.9 Million - $196 Million	-15,000,000 Closed	0 $0
Q2 2020 Aug 13, 2020	SELL	$6.67 - $13.58 $16.9 Million - $34.3 Million	-2,527,968 Reduced 14.42%	15,000,000 $204 Million
Q1 2020 May 14, 2020	SELL	$4.1 - $10.24 $8.38 Million - $20.9 Million	-2,043,485 Reduced 10.44%	17,527,968 $133 Million
Q4 2019 Feb 13, 2020	SELL	$3.16 - $6.73 $15.5 Million - $33 Million	-4,900,000 Reduced 20.02%	19,571,453 $124 Million
Q4 2018 Feb 13, 2019	BUY	$5.39 - $9.15 $132 Million - $224 Million	24,471,453 New	24,471,453 $135 Million

120

54.9M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $438M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Baupost Group LLC, based on Form 13F filings with the SEC.

Stay updated on Baupost Group LLC and Seth Klarman with notifications on news.